Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2025-12-24 @ 6:59 PM
NCT ID:
NCT07272057
Brief Summary:
The goal of this clinical trial
The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:
* Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
* Does it cause more or fewer cardiovascular toxicity?
* What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.
Participants will:
* Be adults diagnosed with advanced lung cancer and type 2 diabetes.
* Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
* Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies
Study:
NCT07272057
Study Brief:
Protocol Section:
NCT07272057